TY - JOUR
T1 - Body composition changes in patients with systolic heart failure treated with beta blockers
T2 - A pilot study
AU - Lainscak, Mitja
AU - Keber, Irena
AU - Anker, Stefan D.
PY - 2006/1/26
Y1 - 2006/1/26
N2 - Background: Cachexia is an independent risk factor for mortality in chronic heart failure (CHF). Beta blockers can reduce body energy expenditure and improve efficiency of substrate utilization. Aim: To assess the changes in body composition in non-cachectic patients with CHF treated with beta blockers. Methods: We prospectively followed 41 non-cachectic ambulatory CHF patients (mean age 67 ± 10 years, ejection fraction 37 ± 4%) treated with beta blockers for at least 6 months. Body composition was measured by bioimpedance. Results: At baseline 16/41 patients were treated with beta blockers while at the end of follow-up all patients received beta blockers (31/41 at full recommended dose). During follow up of 263 ± 106 days body weight (83.1 ± 16.7 vs. 83.0 ± 16.9 kg), body mass index (29.3 ± 5.5 vs. 29.3 ± 5.6) and total body water did not change (51.2 ± 6.4% vs. 51.0 ± 6.4%), while total body fat mass (27.4 ± 9.6 to 28.3 ± 10.2 kg, median change + 0.89 kg, p = 0.01) and percent of total body fat increased (32.3 ± 7.4% to 33.4 ± 7.5%, median change + 0.7%, p <0.001). New York Heart Association class and Minnesota Living with Heart Failure Questionnaire improved from 2.9 ± 0.4 and 48 ± 15 to 2.3 ± 0.6 and 32 ± 16, respectively (p <0.001 for both). Conclusion: In patients with CHF, treatment with beta blockers can increase total body fat mass and total body fat content.
AB - Background: Cachexia is an independent risk factor for mortality in chronic heart failure (CHF). Beta blockers can reduce body energy expenditure and improve efficiency of substrate utilization. Aim: To assess the changes in body composition in non-cachectic patients with CHF treated with beta blockers. Methods: We prospectively followed 41 non-cachectic ambulatory CHF patients (mean age 67 ± 10 years, ejection fraction 37 ± 4%) treated with beta blockers for at least 6 months. Body composition was measured by bioimpedance. Results: At baseline 16/41 patients were treated with beta blockers while at the end of follow-up all patients received beta blockers (31/41 at full recommended dose). During follow up of 263 ± 106 days body weight (83.1 ± 16.7 vs. 83.0 ± 16.9 kg), body mass index (29.3 ± 5.5 vs. 29.3 ± 5.6) and total body water did not change (51.2 ± 6.4% vs. 51.0 ± 6.4%), while total body fat mass (27.4 ± 9.6 to 28.3 ± 10.2 kg, median change + 0.89 kg, p = 0.01) and percent of total body fat increased (32.3 ± 7.4% to 33.4 ± 7.5%, median change + 0.7%, p <0.001). New York Heart Association class and Minnesota Living with Heart Failure Questionnaire improved from 2.9 ± 0.4 and 48 ± 15 to 2.3 ± 0.6 and 32 ± 16, respectively (p <0.001 for both). Conclusion: In patients with CHF, treatment with beta blockers can increase total body fat mass and total body fat content.
KW - Beta blockers
KW - Bioimpedance
KW - Body fat mass
KW - Heart failure
UR - http://www.scopus.com/inward/record.url?scp=28844438290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28844438290&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2005.01.061
DO - 10.1016/j.ijcard.2005.01.061
M3 - Article
C2 - 16337039
AN - SCOPUS:28844438290
VL - 106
SP - 319
EP - 322
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 3
ER -